Look back at pharma news to Apr 21

23 April 2017

By Barbara Obstoj-Cardwell. Editor

US health care giant Johnson & Johnson kicked of the first-quarter financial results with a mixed bunch of figures. The coming week will see results from more pharma and biotech majors, including AbbVie, Amgen, Biogen and Bristol-Myers in the USA, as well as AstraZeneca, Bayer, GSK, Novartis and Roche in Europe. Also attracting attention last week was Ultragenyx with its burosumab, and disappointing news for AbbVie’s veliparib. There was also news from Canada’s Valeant Pharmaceuticals International regarding launch plans for its new psoriasis treatment Siliq.

Is J&J at the mercy of the business cycle?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK